{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T04:41:56Z","timestamp":1774154516445,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.tjog.2024.05.020","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T22:59:38Z","timestamp":1726009178000},"page":"601-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"63","author":[{"given":"Nicholas","family":"Adrianto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghea","family":"Mangkuliguna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunike Jennifer","family":"Tandiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candra Novi Ricardo","family":"Sibarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2024.05.020_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.tjog.2024.05.020_bib2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2019.05.014","article-title":"Ovarian cancer relapse: from the latest scientific evidence to the best practice","volume":"140","author":"Luvero","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.tjog.2024.05.020_bib4","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: what is the best management?","volume":"9","author":"Garzon","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.tjog.2024.05.020_bib5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s12094-020-02545-x","article-title":"SEOM clinical guideline in ovarian cancer (2020)","volume":"23","author":"Redondo","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2024.05.020_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918778483","article-title":"Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy","volume":"10","author":"Dal Molin","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib8","first-page":"4203","article-title":"Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy","volume":"22","author":"Valabrega","year":"2021","journal-title":"Indian J Manag Sci"},{"key":"10.1016\/j.tjog.2024.05.020_bib9","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/TCRM.S149248","article-title":"Targeted treatment of advanced ovarian cancer: spotlight on rucaparib","volume":"14","author":"Pearre","year":"2018","journal-title":"Therapeut Clin Risk Manag"},{"key":"10.1016\/j.tjog.2024.05.020_bib10","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.tjog.2024.05.020_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.tjog.2024.05.020_bib12","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.tjog.2024.05.020_bib13","series-title":"MedCalc, version 19.5.1","year":"2020"},{"key":"10.1016\/j.tjog.2024.05.020_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2024.05.020_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41416-022-02022-y","article-title":"Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10","volume":"128","author":"Kristeleit","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tjog.2024.05.020_bib16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib17","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjog.2024.05.020_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib19","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A\u00a0phase I\u2013II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2 -mutated ovarian carcinoma or other solid tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjog.2024.05.020_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1186\/s12885-022-10191-5","article-title":"Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain \u2013 a GEICO study","volume":"22","author":"Yubero","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tjog.2024.05.020_bib21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Ledermann","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.tjog.2024.05.020_bib23","series-title":"Williams gynecology. 4th ed","author":"Hoffman","year":"2020"},{"key":"10.1016\/j.tjog.2024.05.020_bib24","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2024.05.020_bib26","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.05.020_bib27","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2024.05.020_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.tjog.2024.05.020_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2024.05.020_bib30","first-page":"3468","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J\u00a0Clin Orthod"},{"key":"10.1016\/j.tjog.2024.05.020_bib31","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/DDDT.S164553","article-title":"Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials","volume":"12","author":"Liu","year":"2018","journal-title":"DDDT"},{"key":"10.1016\/j.tjog.2024.05.020_bib32","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.11951","article-title":"PARP inhibitors and epithelial ovarian cancer: molecular mechanisms, clinical development and future prospective (Review)","volume":"20","author":"Loizzi","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.tjog.2024.05.020_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2022.2151883","article-title":"Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis","volume":"43","author":"Yang","year":"2023","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.tjog.2024.05.020_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2019.06.012","article-title":"Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials","volume":"141","author":"Ruiz-Schutz","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.tjog.2024.05.020_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.11.029","article-title":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged \u226565 years from the PAOLA-1\/ENGOT-ov25 trial","volume":"181","author":"Sabatier","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2024.05.020_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr Oncol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455924001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455924001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T22:59:53Z","timestamp":1726009193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455924001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1028455924001670"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2024.05.020","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2024.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}